"No centrifuging was necessary [while using the CLARiTY] to collect data you will like. It is very different. And very superior to results from the Johnson Foundation [dual wavelength] instrument's spectra. We will be publishing soon."
Prof Robert Poole, May 2013
Interaction of the carbon monoxide-releasing molecule Ru(CO)3Cl(glycinate) (CORM-3) with Salmonella enterica serovar Typhimurium: in situ measurements of CO binding by integrating cavity dual beam spectrophotometry
Microbiology, 2014, Published online ahead of print, 8.1.14
Introducing [Mn(CO)3(tpa-κ3N)]+ as a novel photoactivatable CO-releasing molecule with well-defined iCORM intermediates – synthesis, spectroscopy, and antibacterial activity
Dalton Trans., 2014,43, 9986-9997
Figure from Dr. Poole's Microbiology paper comparing spectra of Salmonella in situ with a Standard Dual Beam UV/Vis (A) and the CLARiTY (B).
Dr. Poole’s story:
Robert Poole had known the reputation of Richard DeSa for many years, because of a shared acquaintance with Quentin Gibson and colleagues who had purchased OLIS spectrophotometers, but it was when he was in the market for a stopped-flow spectrometer himself that their conversation started. Robert quickly saw the superior performance of the OLIS RSM 1000 rapid-scanning spectrophotometer over diode array detection for stopped-flow studies. And, when he learned that DeSa had developed a second application for this RSM 1000 – the scatter immune CLARiTY – the decision to choose OLIS was made. Poole became only the second scientist in the world to purchase a CLARiTY and the first in the UK. After a year of fruitful kinetic studies, his group turned their attention to the CLARiTY, quickly confirming firsthand that the results were “very different and very superior” to those from the Johnson Foundation dual wavelength spectrometer they have long relied upon for turbid samples. In January 2014, Poole reported “So, three different bacteria, 3 Olis papers!” Unknown to him, in 2010, John S. Olson (like DeSa, a former member of Gibson’s laboratory) anticipated “If Robert [Poole] and his crew can do whole bacteria experiments successfully with in vivo flavoHb and other globins, the system will sell itself.”
Congratulations and continuing success to the purchaser of CLARiTY #2 (the model 1000), who describes his work as “to understand the structure, function, molecular genetics and biosynthesis of microbial respiratory proteins, especially the terminal oxidases and hemoglobins of bacteria. In addition, we work on the bioinorganic chemistry of metal function and toxicity in microorganisms, and the influence of oxygen levels in bacterial biofilms.”
Robert K. Poole, Ph.D.
Professor & West Riding Chair in Microbiology
University of Sheffield